CN112899307A - Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors - Google Patents

Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors Download PDF

Info

Publication number
CN112899307A
CN112899307A CN202110121175.8A CN202110121175A CN112899307A CN 112899307 A CN112899307 A CN 112899307A CN 202110121175 A CN202110121175 A CN 202110121175A CN 112899307 A CN112899307 A CN 112899307A
Authority
CN
China
Prior art keywords
glun1
myristoylated
seq
glun2
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110121175.8A
Other languages
Chinese (zh)
Inventor
周亮
王步凇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou University
Original Assignee
Suzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou University filed Critical Suzhou University
Priority to CN202110121175.8A priority Critical patent/CN112899307A/en
Publication of CN112899307A publication Critical patent/CN112899307A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses application of GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor, and provides application of GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor, wherein the application is to apply GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor to development of neurodevelopmental or neuropathy medicines. The carboxyl terminal of the myristoylated GluN2A is an irreversible fatty acid modification, can directly transfect cells, is used for researching the regulation and control of the myristoylation on GluN2A functions, and has wide application prospects in the fields of medicines and the like.

Description

Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to application of a GluN1 and/or GluN2 subunit carboxyl terminal myristoylation NMDA receptor.
Background
In the field of biology, mutations and aberrant expression of the NMDA receptor have a serious impact on cerebral neurodegeneration and the treatment of related neurological disorders. The study of NMDA receptor structure and function has been a focus in the neuroscience field. The classical NMDA receptor consists of two GluN1 subunits and two GluN2(2A/2B) subunits, which are multi-transmembrane proteins, which all add to the difficulty of studying NMDA receptors. The existing research shows that the NMDA receptor carboxyl terminal controls the signal transduction function, and the research on the NMDA receptor carboxyl terminal is very important for developing corresponding drug targets. Early studies found that palmitoylation could modulate NMDA receptor function by modifying the GluN2A and GluN2B subunits of the NMDA receptor. Palmitoylation is a fatty acid modification that can localize proteins to the cell membrane, which provides a convenience for the study of NMDA receptors. Palmitoylation can position the carboxyl terminal of the NMDA receptor on a cell membrane, so that the positioning of normal NMDA receptor subunits in cells can be simulated, and the function of the NMDA receptor in a normal state can be simulated more truly. However, palmitoylation-modified NMDA receptors present modified abscission and large amounts of unmodified proteins, which limits the utility of this modification.
Disclosure of Invention
In order to solve the technical problems, the invention provides application of GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor.
The first purpose of the invention is to provide an application of GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor, wherein the application is to apply GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor to the development of neurodevelopmental or neuropathy medicines.
Further, the myristoylation is performed by adding a conserved sequence capable of being myristoylated at the carboxy terminus of GluN1 and/or GluN 2.
Furthermore, the amino acid sequence of the conserved sequence is shown as SEQ ID NO. 1.
Further, the nucleotide sequence of the conserved sequence is shown as SEQ ID NO. 2.
Further, primer pairs of GluN1 added with conserved sequences are shown as SEQ ID NO.3 and SEQ ID NO. 4.
Further, in GluN2 added with a conserved sequence, a primer pair of GluN2A is shown as SEQ ID NO.5 and SEQ ID NO. 6; primer pairs of GluN2B are shown as SEQ ID NO.7 and SEQ ID NO. 8.
Further, in the use, there is included modulating membrane localization of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors with positively charged amino acids.
Further, in the use, modulation of membrane localization of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors with phosphorylation modifications is also included.
It is a second object of the present invention to provide a plasmid expressing GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptor.
The third purpose of the invention is to provide the application of the plasmid in the development of medicines for neurodevelopment or neuropathy.
By the scheme, the invention at least has the following advantages:
the carboxyl terminal of the myristoylated GluN2A is an irreversible fatty acid modification, can directly transfect cells, is used for researching the regulation and control of the myristoylation on GluN2A functions, and has wide application prospects in the fields of medicines and the like.
The foregoing is a summary of the present invention, and in order to provide a clear understanding of the technical means of the present invention and to be implemented in accordance with the present specification, the following is a preferred embodiment of the present invention and is described in detail below.
Drawings
FIG. 1 is a fluorescent plot of the carboxyl terminus of myristoylated GluN1 expressed in cells;
FIG. 2 is a fluorescent plot of intracellular expression of myristoylated GluN2A and GluN2B carboxyl termini;
FIG. 3 is a fluorescent map of the carboxyl terminus localization of myristoylated GluN1 to cell membrane;
FIG. 4 is a fluorescent control plot of myristoylated GluN1 with phosphorylation-modified carboxy-terminal localization.
Detailed Description
Example 1:
construction of the carboxyl termini of myristoylated GluN1, GluN2A and GluN2B:
(1) the myristoylation conserved sequence is derived from the protein MARCKS front-end sequence: MGAQFSK.
The corresponding nucleotides are: ATGGGTGCCCAGTTCTCCAAG are provided.
(2) Primers were custom made with the myristoylation conserved sequence as follows:
GluN1:5 '-3' (with myristoylation conserved sequence): TCGGCTAGCACCATG GGTGCCCAGTTCTCCAAGATCGCCTACAAGCGACACAAGGATGCC, respectively; 3'-5': AGCTGTCGACGCTCTCCCTATGACGGGAACACAGCTGCAG are provided.
GluN2A:5 '-3' (with myristoylation conserved sequence): TCGGCTAGCACCATG GGTGCCCAGTTCTCCAAGACCTCTTCTACTGGAAGCTGCGCTTCTG, respectively; 3'-5': AGCTGTCGACAACATCAGATTCGATACTAGGCATTTTC are provided.
GluN2B:5 '-3' (with myristoylation conserved sequence): TCGGCTAGCACCATG GGTGCCCAGTTCTCCAAGCATCTGTTCTATTGGCAGTTCCGGCATTG, respectively; 3'-5': AGCTGTCGACGACATCAGACTCAATACTAGAAAGTTTC are provided.
(3) GluN1, GluN2A and GluN2B plasmids were used as templates for conventional PCR. (PCR kit available from TaKaRa Co., Ltd.) system. The PCR system (25. mu.L) was as follows (unit:. mu.L):
10×Buffer:2.5,
dNTP:2,
Taq:0.5；
primer:2；
vector:300ng。
(4) performing PCR, wherein the PCR conditions are as follows:
(4.1) one cycle, 30 seconds at 95 ℃;
(4.2)30 cycles of 95 ℃ for 30 seconds, 58 ℃ for 30 seconds and 72 ℃ for 2 minutes;
(4.3) one cycle, 10 minutes at 72 ℃.
(5) Agarose gel electrophoresis was performed, and the nucleic acid gel was recovered and digested with NEB fast-cutting enzymes Nhe I and Sal I for 20 minutes. The pEGFP-N3 vector is connected, and the bacteria are selected to be correctly sequenced after transformation and plating.
Example 2:
expression of the carboxyl terminus of myristoylated GluN1:
the myristoylated carboxy-terminal plasmid was transfected into HEK293 cells and after 24 hours the fluorescent signal was detected. The results are shown in FIG. 1 (scale bar: 20 μm), and it can be seen that this myristoylated GluN1 carboxy terminus is well expressed in eukaryotic cells. The invention provides a tool for researching fatty acid modified GluN 1.
Expression of myristoylated GluN2A and GluN2B carboxyl termini:
the myristoylated carboxy-terminal plasmid was transfected into HEK293 cells and after 24 hours the fluorescent signal was detected. The results are shown in FIG. 2 (scale: 20 μm), and it can be seen that this myristoylated GluN2A and GluN2B carboxy terminus are well expressed in eukaryotic cells. The invention provides a tool for researching fatty acid modified GluN 2.
Example 3:
localization of the carboxyl terminus of myristoylated GluN1 was regulated by positively charged amino acids:
the plasmid myristoylated GluN1 carboxyl-terminal was transfected into HEK293 cells and fluorescence signals were detected 24 hours later. The results are shown in FIG. 3 (scale: 20 μm), and the box shows that the carboxyl terminus of this myristoylated GluN1 is able to localize to the cell membrane.
The carboxy terminus of GluN1 contained a 9 positively charged C1 region. Mutating the 10 positively charged amino acids of the C1 region to uncharged alanines (fig. 3A) can significantly reduce the cell membrane localization of the carboxyl terminus of the myristoylated GluN1 (fig. 3B).
Example 4:
localization of the carboxyl terminus of myristoylated GluN1 was regulated by phosphorylation modifications:
the plasmid myristoylated GluN1 carboxyl-terminal was transfected into HEK293 cells and fluorescence signals were detected 24 hours later. The results are shown in FIG. 4 (scale bar: 20 μm), and it can be seen in the box that the localization of the cell membrane at the carboxy terminus of this myristoylated GluN1 was regulated by phosphorylation modification.
GluN1 has 6 sites (tyrosine T and serine S) at the carboxy-terminal C1 region that can be modified by phosphorylation (FIG. 4A). Mutation of the 6 phosphorylation sites in the C1 region to alanines that could not be modified by phosphorylation (FIG. 4B) did not alter the cell membrane localization of the carboxyl terminus of myristoylated GluN 1. However, if 6 phosphorylation sites in the C1 region were mutated to mimic phosphorylation modified glutamate (E) and aspartate (D) (fig. 4B), the cell membrane localization of the carboxyl terminus of myristoylated GluN1 could be significantly reduced (fig. 4C).
The above is only a preferred embodiment of the present invention, and is not intended to limit the present invention, it should be noted that, for those skilled in the art, many modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> Suzhou university
<120> use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors
<141> 2021-01-28
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7
<212> PRT
<213> (Artificial sequence)
<400> 1
Met Gly Ala Gln Phe Ser Lys
1 5
<210> 2
<211> 21
<212> DNA
<213> (Artificial sequence)
<400> 2
atgggtgccc agttctccaa g 21
<210> 3
<211> 60
<212> DNA
<213> (Artificial sequence)
<400> 3
tcggctagca ccatgggtgc ccagttctcc aagatcgcct acaagcgaca caaggatgcc 60
<210> 4
<211> 40
<212> DNA
<213> (Artificial sequence)
<400> 4
agctgtcgac gctctcccta tgacgggaac acagctgcag 40
<210> 5
<211> 61
<212> DNA
<213> (Artificial sequence)
<400> 5
tcggctagca ccatgggtgc ccagttctcc aagacctctt ctactggaag ctgcgcttct 60
g 61
<210> 6
<211> 38
<212> DNA
<213> (Artificial sequence)
<400> 6
agctgtcgac aacatcagat tcgatactag gcattttc 38
<210> 7
<211> 62
<212> DNA
<213> (Artificial sequence)
<400> 7
tcggctagca ccatgggtgc ccagttctcc aagcatctgt tctattggca gttccggcat 60
tg 62
<210> 8
<211> 38
<212> DNA
<213> (Artificial sequence)
<400> 8
agctgtcgac gacatcagac tcaatactag aaagtttc 38

Claims (10)

1. The application of the GluN1 and/or GluN2 subunit carboxyl-terminal myristoylated NMDA receptor is characterized in that the GluN1 and/or GluN2 subunit carboxyl-terminal myristoylated NMDA receptor is applied to the development of a medicament for neurodevelopment or neuropathy.
2. The use according to claim 1, wherein the myristoylation is performed by adding a conserved sequence capable of being myristoylated at the carboxy terminus of GluN1 and/or GluN 2.
3. The use of claim 1, wherein the amino acid sequence of said conserved sequence is as shown in SEQ ID No. 1.
4. The use of claim 1, wherein the nucleotide sequence of said conserved sequence is shown in SEQ ID No. 2.
5. The use according to claim 4, wherein primer pair of GluN1 with conserved sequence added is shown as SEQ ID No.3 and SEQ ID No. 4.
6. The use according to claim 4, wherein, in GluN2 with the addition of conserved sequences, the primer pair of GluN2A is shown as SEQ ID No.5 and SEQ ID No. 6; primer pairs of GluN2B are shown as SEQ ID NO.7 and SEQ ID NO. 8.
7. The use of claim 1, further comprising modulating membrane localization of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors with positively charged amino acids.
8. The use of claim 1, further comprising modulating membrane localization of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors with phosphorylation modifications.
9. A plasmid expressing GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors.
10. Use of the plasmid of claim 9 in the development of a medicament for neurodevelopment or neuropathy.
CN202110121175.8A 2021-01-28 2021-01-28 Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors Pending CN112899307A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110121175.8A CN112899307A (en) 2021-01-28 2021-01-28 Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110121175.8A CN112899307A (en) 2021-01-28 2021-01-28 Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors

Publications (1)

Publication Number Publication Date
CN112899307A true CN112899307A (en) 2021-06-04

Family

ID=76119946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110121175.8A Pending CN112899307A (en) 2021-01-28 2021-01-28 Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors

Country Status (1)

Country Link
CN (1) CN112899307A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246934A1 (en) * 2021-05-28 2022-12-01 苏州大学 Myristoylated polypetide encoding mitochondrial localization, and preparation method therefor and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057614A1 (en) * 2004-08-04 2006-03-16 Nathaniel Heintz Tethering neuropeptides and toxins for modulation of ion channels and receptors
WO2020101740A1 (en) * 2018-11-16 2020-05-22 Codiak Biosciences, Inc. Engineered extracellular vesicles and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057614A1 (en) * 2004-08-04 2006-03-16 Nathaniel Heintz Tethering neuropeptides and toxins for modulation of ion channels and receptors
WO2020101740A1 (en) * 2018-11-16 2020-05-22 Codiak Biosciences, Inc. Engineered extracellular vesicles and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRYCE VISSEL等: "A use-dependent tyrosine dephosphorylation of NMDA receptors is independent of ion flux", 《NATURE NEUROSCIENCE》 *
傅展燕: "活细胞可视化研究NMDA受体在神经元的表面表达、分布及其与突触形成和功能的关系", 《中国博士学位论文全文数据库》 *
郑婵颖等: "NMDA受体 NR2A亚单位C末端突变体在HEK293细胞的共表达研究", 《浙江大学学报（医学版）》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246934A1 (en) * 2021-05-28 2022-12-01 苏州大学 Myristoylated polypetide encoding mitochondrial localization, and preparation method therefor and use thereof

Similar Documents

Publication Publication Date Title
US11525125B2 (en) Modified helicases
US11525126B2 (en) Modified helicases
US20180230526A1 (en) Enzyme construct
US10752948B2 (en) Alpha-hemolysin variants
US10590480B2 (en) Polymerase variants
Legrain et al. The molecular characterization of PRP6 and PRP9 yeast genes reveals a new cysteine/histidine motif common to several splicing factors.
AU2013246702A1 (en) Mutant lysenin pores
ES2880331T3 (en) Polymerase variants
CN112041331B (en) Alpha-hemolysin variants and uses thereof
CN109937252B (en) Recombinant DNA polymerase
Liu et al. Molecular cloning and expression analysis of a new gene for short-chain dehydrogenase/reductase 9
CN111269325B (en) Fusion protein of light-regulated BK channel and preparation method and application thereof
CN112899307A (en) Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors
CN102671185A (en) Application of scolopendra mutilans neurotoxin peptide omega-SLPTX-Ssmla
CN104844691B (en) Sox2 protein peptides aptamer and its identification
WO2022109058A1 (en) Nucleases comprising cell penetrating peptide sequences
Briot et al. Three-dimensional architecture of the L-type calcium channel: structural insights into the Cavα2δ1 auxiliary protein
WO2022246934A1 (en) Myristoylated polypetide encoding mitochondrial localization, and preparation method therefor and use thereof
CN114057893B (en) Myristoylation polypeptide for encoding mitochondrial localization and preparation method and application thereof
CN115777019A (en) Modified Prp43 helicases and uses thereof
Kim et al. New fast BiFC plasmid assay system for in vivo protein-protein interactions
WO2003057827A3 (en) Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
Turek et al. The discovery of hidden guanylate cyclases (GCs) in the Homo sapiens proteome
KR20060135644A (en) High troughput functional assay for g-protein coupled receptors using a rap-ras chimeric protein
Iwasaki et al. A novel importin α from rice, a component involved in the process of nuclear protein transport

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination